When a company acquires another business for more than the fair value of its identifiable assets, the difference is recorded as goodwill on the balance sheet. That asset is not amortized under current accounting standards for most companies, but it must be tested for impairment, and a write-down is effectively an admission that the acquisition has not delivered what was paid for.
Impairment announcements usually arrive with little warning from the company’s perspective but considerable warning from the numbers. The test is triggered when the fair value of a reporting unit falls below its carrying value, and the conditions that cause this, such as declining revenue, rising discount rates, or a lower stock price, are typically visible well in advance.
A write-down is a non-cash charge, which leads some investors to dismiss it. That reaction misses the point. The charge does not change current cash flows, but it reveals that management overpaid, and the capital that went into the deal is not earning the return originally projected.
Goodwill as a share of total assets and of shareholder equity shows how exposed a company is. A business where goodwill makes up a large portion of equity can see its book value fall sharply after an impairment, and in cases of covenant-heavy debt, the balance sheet effect can trigger compliance issues even though no cash has left the company.
Timing frequently lags reality. Companies often delay impairment charges until a poor quarter makes them harder to avoid, and the write-down may come years after the acquisition began underperforming. Comparing the acquired unit’s disclosed results against the deal’s original projections shows how far behind the recognition may be.
Serial acquirers deserve particular attention, since a pattern of acquisitions followed by impairments suggests a systematic problem in either valuation discipline or integration capability rather than a single unlucky deal.
A forward-looking check is to compare the carrying value of goodwill against the market value of the business unit when that information can be inferred. When a company’s market capitalization falls below its book value, accounting rules make an impairment test more likely, and the size of the gap indicates how large a charge could be. Watching for these conditions allows investors to anticipate write-downs rather than react to them, and to ask whether management’s original acquisition thesis still holds up against the unit’s recent revenue and margin trends.
Following acquisitions from announcement through eventual write-downs, as BullScope’s ongoing market news coverage does, lets investors hold deal rationales accountable to the results that follow.
This article is educational and does not replace individualized medical advice, diagnosis or treatment.
Keep your momentum.
Use the next and previous guide controls to continue through connected health topics.
